Quantum Biopharma (QNTM) Current Leases (2019 - 2026)
Quantum Biopharma's (QNTM) quarterly Current Leases came in at $83991.0 in Q1 2026, up 137.54% year-on-year from $35358.0 in Q1 2025, and down 18.59% quarter-over-quarter from $103165.0 in Q4 2025.
Quantum Biopharma (QNTM) Current Leases (2019 - 2026) Analysis & Trends
Quantum Biopharma has disclosed Current Leases across 8 years of filings, most recently posting $83991.0 for Q1 2026.
- Current Leases for Q1 2026 came in at $83991.0, up 137.54% year-over-year; the trailing twelve-month figure through Mar 2026 was $83991.0 (up 137.54% YoY), and the FY2025 annual result was $103165.0, up 91.83% from the prior year.
- Current Leases came in at $83991.0 for Q1 2026 at Quantum Biopharma, down from $103165.0 in the prior quarter.
- In the past five years, Current Leases ranged from a high of $198273.0 in Q3 2022 to a low of $9634.0 in Q2 2024.
- The 5-year median for Current Leases is $107202.0 (2023), against an average of $111533.3.
- Across the five-year window, Current Leases sank 91.01% in 2024 and soared 1525.2% in 2025, its largest moves.
- Quantum Biopharma's Current Leases stood at $177870.0 in 2022, then slumped by 64.97% to $62308.0 in 2023, then dropped by 13.69% to $53780.0 in 2024, then soared by 91.83% to $103165.0 in 2025, then declined by 18.59% to $83991.0 in 2026.
- The last three Current Leases figures came in at $83991.0 (Q1 2026), $103165.0 (Q4 2025), and $151798.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 42,980.09 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 83,991.00 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 7.40 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Regeneron Pharmaceuticals | 63.43 Bn | 54.67 Bn | 3.31 Bn | 720.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 83,991.00 |
| Dec 31, 2025 | 103,165.00 |
| Sep 30, 2025 | 151,798.00 |
| Jun 30, 2025 | 156,572.00 |
| Mar 31, 2025 | 35,358.00 |
| Dec 31, 2024 | 53,780.00 |
| Sep 30, 2024 | 72,475.00 |
| Jun 30, 2024 | 9,634.00 |
| Sep 30, 2023 | 62,308.00 |
| Jun 30, 2023 | 107,202.00 |
| Mar 31, 2023 | 141,702.00 |
| Dec 31, 2022 | 177,870.00 |
| Sep 30, 2022 | 198,273.00 |
| Jun 30, 2022 | 158,976.00 |
| Mar 31, 2022 | 159,895.00 |
| Dec 31, 2021 | 124,311.00 |
| Sep 30, 2021 | 50,126.00 |
| Jun 30, 2021 | 61,626.00 |
| Mar 31, 2021 | 70,513.00 |
| Dec 31, 2020 | 46,842.00 |